Adverse events in patients with blood loss: a pooled analysis of 51 clinical studies from the celecoxib clinical trial database.

Sands G, Shell B, Zhang R
Open Rheumatol J 2012;6:44-49.
NATA Rating :
Review by : J. L. Carson
NATA Review

This analysis compared adverse event rates in patients with significant blood loss versus those without this complication in trials evaluating the nonsteroidal anti-inflammatory drugs celecoxib. An association was found between significant blood loss and serious cardiac complications. This study suggests that patients who bleed more frequently have underlying cardiac disease, rather that anemia leads to myocardial infarction.

Jeffrey L. Carson

Consent Management Platform by Real Cookie Banner